// App-Quantinova.ai

: Late Breaking Abstract - Cost effectiveness of as-needed budesonide/formoterol vs low-dose ICS maintenance therapy in mild asthma patients: A UK perspective

Researchers

Presenter

  • J. Mark FitzGerald

Principal Investigators

  • Sofie Arnetorp

  • Caitlin Smare

  • Danny Gibson

  • Karen Coulton

  • Kirsty Hounsell

  • Mohsen Sadatsafavi

Medical Centers

  • Institute for Heart and Lung Health, University of British Columbia, Vancouver, BC, Canada,

  • AstraZeneca, Gothenburg, Sweden

  • 2PAREXEL International, London, UK London United Kingdom

  • AstraZeneca, Royston, United Kingdom

  • Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada

Locations

  • Canada

  • Sweden

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Asthma

Biomarkers

  • N/A

Drug/Treatment

  • budesonide + formoterol fuma

  • Terbutaline

  • Budesonide

  • Formoterol

  • Eos-200-4

Outcome

  • N/A

Study Design

  • Double Blind/Blinded

Phase

  • NA

Study Id's

  • NCT02224157

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved